Literature DB >> 20025692

Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort.

N Manabe1, B S Wong, M Camilleri, D Burton, S McKinzie, A R Zinsmeister.   

Abstract

BACKGROUND Abnormalities of colonic motility were reported in relatively small studies of patients with lower functional gastrointestinal disorders (FGID) including irritable bowel syndrome (IBS). The influence of gender and body mass on the observed motor pathophysiology is unclear. We sought to compare colonic transit in patients within different lower FGID subgroups and healthy controls, controlling for gender and BMI, and to determine whether BMI independently influences colonic motility. METHODS We evaluated a scintigraphic gastrointestinal and colonic transit database of 287 lower FGID patients associated with constipation (IBS-C, or functional constipation, n = 118), diarrhoea (IBS-D or functional diarrhoea, n = 139) or mixed bowel function (IBS-M, n = 30) and 170 healthy controls. We measured colon filling at 6 h (CF 6 h), and overall colonic transit at 8, 24 and 48 h. KEY RESULTS Colon filling at 6 h did not differentiate health from FGID. Colonic transit was abnormal at 24 h (GC24 of <1.50 or >3.86) in 29.7% of all lower FGID patients. There was a significant overall association between colonic transit and subject group (healthy controls and FGID subgroups) at 8 (P = 0.01), 24 (P < 0.001) and 48 h (P < 0.001) in particular for those with diarrhoea or constipation at 24 and 48 h (P < 0.05), even after adjusting for age, gender and BMI. In addition, BMI was associated with colonic transit after adjusting for age, gender and subject group. CONCLUSIONS &amp; INFERENCES Abnormal transit is documented non-invasively with scintigraphy in 30% of lower FGID patients; transit measurement may help document pathophysiology and inform selection of therapy in lower FGID.

Entities:  

Mesh:

Year:  2009        PMID: 20025692      PMCID: PMC2852497          DOI: 10.1111/j.1365-2982.2009.01442.x

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  55 in total

1.  Different segmental transit times in patients with irritable bowel syndrome and "normal" colonic transit time: is there a correlation with symptoms?

Authors:  M Bouchoucha; G Devroede; E Dorval; A Faye; P Arhan; M Arsac
Journal:  Tech Coloproctol       Date:  2006-11-27       Impact factor: 3.781

2.  Gastric emptying is accelerated in obese type 2 diabetic patients without autonomic neuropathy.

Authors:  E Bertin; N Schneider; N Abdelli; H Wampach; G Cadiot; A Loboguerrero; M Leutenegger; J C Liehn; G Thiefin
Journal:  Diabetes Metab       Date:  2001-06       Impact factor: 6.041

3.  Effects of an alpha(2)-adrenergic agonist on gastrointestinal transit, colonic motility, and sensation in humans.

Authors:  B E Viramontes; A Malcolm; M Camilleri; L A Szarka; S McKinzie; D D Burton; A R Zinsmeister
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2001-12       Impact factor: 4.052

4.  Clinical patterns over time in irritable bowel syndrome: symptom instability and severity variability.

Authors:  Fermin Mearin; Eva Baró; Montse Roset; Xavier Badía; Natalia Zárate; Isabel Pérez
Journal:  Am J Gastroenterol       Date:  2004-01       Impact factor: 10.864

5.  Accelerated regional bowel transit and overweight shown in idiopathic bile acid malabsorption.

Authors:  Riadh Sadik; Hasse Abrahamsson; Kjell-Arne Ung; Per-Ove Stotzer
Journal:  Am J Gastroenterol       Date:  2004-04       Impact factor: 10.864

6.  Performance characteristics of scintigraphic transit measurements for studies of experimental therapies.

Authors:  F Cremonini; B P Mullan; M Camilleri; D D Burton; M R Rank
Journal:  Aliment Pharmacol Ther       Date:  2002-10       Impact factor: 8.171

7.  Prevalence and trends in obesity among US adults, 1999-2000.

Authors:  Katherine M Flegal; Margaret D Carroll; Cynthia L Ogden; Clifford L Johnson
Journal:  JAMA       Date:  2002-10-09       Impact factor: 56.272

8.  Irritable bowel syndrome subtypes according to bowel habit: revisiting the alternating subtype.

Authors:  Fermín Mearin; Agustín Balboa; Xavier Badía; Eva Baró; Ellen Caldwell; Mercedes Cucala; Manuel Díaz-Rubio; Arturo Fueyo; Julio Ponce; Montse Roset; Nicholas J Talley
Journal:  Eur J Gastroenterol Hepatol       Date:  2003-02       Impact factor: 2.566

9.  Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans.

Authors:  Silvia Delgado-Aros; Heather J Chial; Michael Camilleri; Lawrence A Szarka; Frank T Weber; Jutta Jacob; Irene Ferber; Sanna McKinzie; Duane D Burton; Alan R Zinsmeister
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2003-04       Impact factor: 4.052

10.  A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome.

Authors:  H J Kim; M Camilleri; S McKinzie; M B Lempke; D D Burton; G M Thomforde; A R Zinsmeister
Journal:  Aliment Pharmacol Ther       Date:  2003-04-01       Impact factor: 8.171

View more
  49 in total

1.  HLA-DQ genotype is associated with accelerated small bowel transit in patients with diarrhea-predominant irritable bowel syndrome.

Authors:  Maria I Vazquez-Roque; Michael Camilleri; Paula Carlson; Sanna McKinzie; Joseph A Murray; Tricia L Brantner; Duane D Burton; Alan R Zinsmeister
Journal:  Eur J Gastroenterol Hepatol       Date:  2011-06       Impact factor: 2.566

2.  Genetic susceptibility to inflammation and colonic transit in lower functional gastrointestinal disorders: preliminary analysis.

Authors:  M Camilleri; P Carlson; S McKinzie; M Zucchelli; M D'Amato; I Busciglio; D Burton; A R Zinsmeister
Journal:  Neurogastroenterol Motil       Date:  2011-07-14       Impact factor: 3.598

3.  Association of bile acid receptor TGR5 variation and transit in health and lower functional gastrointestinal disorders.

Authors:  M Camilleri; M I Vazquez-Roque; P Carlson; D Burton; B S Wong; A R Zinsmeister
Journal:  Neurogastroenterol Motil       Date:  2011-08-24       Impact factor: 3.598

Review 4.  American Gastroenterological Association technical review on constipation.

Authors:  Adil E Bharucha; John H Pemberton; G Richard Locke
Journal:  Gastroenterology       Date:  2013-01       Impact factor: 22.682

5.  Irritable bowel syndrome: a multidimensional disorder cannot be understood or treated from a unidimensional perspective.

Authors:  Ami D Sperber; Douglas A Drossman
Journal:  Therap Adv Gastroenterol       Date:  2012-11       Impact factor: 4.409

Review 6.  The bile acid TGR5 membrane receptor: from basic research to clinical application.

Authors:  Henri Duboc; Yvette Taché; Alan F Hofmann
Journal:  Dig Liver Dis       Date:  2014-01-09       Impact factor: 4.088

7.  Novel Therapies in IBS-D Treatment.

Authors:  Judy Nee; Mohammed Zakari; Anthony J Lembo
Journal:  Curr Treat Options Gastroenterol       Date:  2015-12

Review 8.  Chronic Constipation.

Authors:  Adil E Bharucha; Arnold Wald
Journal:  Mayo Clin Proc       Date:  2019-05-01       Impact factor: 7.616

9.  Association of HLA-DQ gene with bowel transit, barrier function, and inflammation in irritable bowel syndrome with diarrhea.

Authors:  Maria I Vazquez-Roque; Michael Camilleri; Thomas Smyrk; Joseph A Murray; Jessica O'Neill; Paula Carlson; Jesse Lamsam; Deborah Eckert; Denise Janzow; Duane Burton; Michael Ryks; Deborah Rhoten; Alan R Zinsmeister
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-10-04       Impact factor: 4.052

Review 10.  Recent advances in pharmacological treatment of irritable bowel syndrome.

Authors:  Georgia Lazaraki; Grigoris Chatzimavroudis; Panagiotis Katsinelos
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.